These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25322965)

  • 1. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study.
    Shoda K; Masuda K; Ichikawa D; Arita T; Miyakami Y; Watanabe M; Konishi H; Imoto I; Otsuji E
    Gastric Cancer; 2015 Oct; 18(4):698-710. PubMed ID: 25322965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
    Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Komatsu S; Shiozaki A; Kakihara N; Okamoto K; Taniguchi H; Imoto I; Otsuji E
    Gastric Cancer; 2017 Jan; 20(1):126-135. PubMed ID: 26874951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
    Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
    BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer.
    Bechmann T; Andersen RF; Pallisgaard N; Madsen JS; Maae E; Jakobsen EH; Bak Jylling AM; Steffensen KD; Jakobsen A
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):995-1003. PubMed ID: 23479212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
    Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
    Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer.
    Ma GF; Liu YM; Gao H; Miao Q; Luo TC; Zeng XQ; Chen SY
    Dig Dis Sci; 2014 Feb; 59(2):328-35. PubMed ID: 24185685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
    Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
    Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery.
    Grenda A; Wojas-Krawczyk K; Skoczylas T; Krawczyk P; Sierocińska-Sawa J; Wallner G; Milanowski J
    BMC Gastroenterol; 2020 Nov; 20(1):382. PubMed ID: 33198632
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between HER2 expression and tumor interstitial angiogenesis in primary gastric cancer and its effect on prognosis.
    Li F; Meng G; Tan B; Chen Z; Ji Q; Wang X; Liu C; Niu S; Li Y; Liu Y
    Pathol Res Pract; 2021 Jan; 217():153280. PubMed ID: 33253925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.
    Kanayama K; Imai H; Yoneda M; Hirokawa YS; Shiraishi T
    Cancer Sci; 2016 Apr; 107(4):536-42. PubMed ID: 26752196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The quantification of HER2 and MYC gene fragments in cell-free plasma as putative biomarkers for gastric cancer diagnosis.
    Park KU; Lee HE; Nam SK; Nam KH; Park DJ; Kim HH; Kim WH; Lee HS
    Clin Chem Lab Med; 2014 Jul; 52(7):1033-40. PubMed ID: 24670359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
    Wang YK; Chen Z; Yun T; Li CY; Jiang B; Lv XX; Chu GH; Wang SN; Yan H; Shi LF
    World J Gastroenterol; 2015 Apr; 21(15):4680-7. PubMed ID: 25914479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.
    Sasaki T; Fuse N; Kuwata T; Nomura S; Kaneko K; Doi T; Yoshino T; Asano H; Ochiai A; Komatsu Y; Sakamoto N; Ohtsu A
    Jpn J Clin Oncol; 2015 Jan; 45(1):43-8. PubMed ID: 25378649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
    Kim ST; Banks KC; Pectasides E; Kim SY; Kim K; Lanman RB; Talasaz A; An J; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Park SH; Park JO; Park YS; Lim HY; Kim NKD; Park W; Lee H; Bass AJ; Kim K; Kang WK; Lee J
    Ann Oncol; 2018 Apr; 29(4):1037-1048. PubMed ID: 29409051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.